No broad tissue-health claim should be made without appropriate clinical evidence for the exact compound, formulation, route, dose, and population
Product claims, intended use, formulation quality, and regulatory context can vary significantly
However, Huberman also noted an important caveat: "There isn't any clinical data for BPC-157
Enzymatic characterization of recombinant rat DDHD2: a soluble diacylglycerol lipase
It does not automatically establish sterility, authorisation, safety or suitability for human or veterinary administration
A formal Phase 2 trial was completed in 2009, but over 15 years later, the results have never been published, another major red flag suggesting it failed to prove effective or safe